Tianda Pharmaceuticals Ltd. reported revenue of HK$136.6 million for the current interim period, down from HK$156.1 million in the previous interim period. The Pharmaceuticals and Medical Technologies business recorded revenue of HK$106.4 million, a decrease of 22.1% compared to HK$136.7 million in the previous interim period. Sales of Tuoen Ibuprofen capsules and Tuoping Valsartan capsules were HK$19.8 million and HK$54.6 million, representing decreases of 22.7% and 17.5% respectively from the previous interim period. Sales of acetylglutamine for injection remained unchanged at HK$5.8 million. The loss before tax for this segment widened to HK$17.2 million from HK$4.9 million in the previous interim period. The Chinese Medicine business reported revenue of HK$18.8 million, up 51.5% from HK$12.4 million in the previous interim period. The loss before tax in this segment narrowed to HK$4.2 million from HK$6.4 million. The Medical and Healthcare services segment recorded revenue of HK$11.4 million, an increase from HK$7.0 million in the previous interim period, with contributions from the newly opened Jordan TDMall Chinese medicine clinic in October 2024. During the period, Tianda Chinese Medicine (Bozhou) Ltd. commenced operations, supporting the varieties management business for Chinese medicinal materials. The company stated it will continue to optimize its domestic business and pursue international market expansion, leveraging Hong Kong's geographical advantages.